## -online.com **Genomics**



Datasheet for ABIN5263163

## Human PTGER1 CRISPR gRNA + Cas9 in Lenti Particles

| Overview              |  |
|-----------------------|--|
| Quantity:             | 300 μL   |
| Gene:                 | PTGER1   |
| Species:              | Human  |
| Insert:               | gRNA + Cas9  |
| Vector:               | Lentiviral Vector  |
| Application:          | Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)   |
| Product Details       |  |
| Purpose:              | Individual gRNA against EP1 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)   |
| Vector Backbone:      | pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro  |
| Promoter:             | U6 Promoter, SFFV Promoter   |
| Selectable Marker:    | Puromycin  |
| Bacterial Resistance: | Ampicillin   |
| Expression Type:      | Stable, Transient  |
| Sequence:             | Sequence available upon placing order  |
| Specificity:          | GRNAs are designed for use with Cas9 Nuclease only.  Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority of cells, except ES cells or iPS cells. |
| Sequencing Primer:    | U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA3'  |
| Components:           | Lentiviral particles with an individual gRNA (300 μL) for a specific sequence of EP1   |

## **Target Details**

| Gene:             | PTGER1                |
|-------------------|-----------------------|
| Alternative Name: | EP1 (PTGER1 Products) |
| NCBI Accession:   | NM_000955             |

| oplication Notes: | Recommended for quality control: Restriction Enzyme Digest and Sequencing |
|-------------------|---|
| estrictions:      | For Research Use only   |
| andling           |   |
| rmat:             | Viral Particles   |
| orage:            | -80 °C  |
| piry Date:        | 12 months   |
| blications        |   |

Product cited in: Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (
1991)